A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor Fitzgerald
BioMarin Pharmaceutical Price Target Maintained With a $110.00/Share by Cantor
Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $110 Price Target
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.44% on an annualized basis producing an average annual return of 14.87%. Currently, Biomarin
Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors
SAN FRANCISCO--(BUSINESS WIRE)--Meliora Therapeutics ("Meliora"), a machine learning therapeutics company developing novel and transformative cancer drugs, today announced the appointment of Dieter
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
Biomarin Pharmaceutical (NASDAQ:BMRN) has outperformed the market over the past 20 years by 6.65% on an annualized basis producing an average annual return of 15.22%. Currently, Biomarin
Piper Sandler Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $107
Piper Sandler analyst Christopher Raymond maintains $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and maintains the target price at $107.According to TipRanks data, the analyst has a success
BioMarin Pharmaceutical (BMRN) Receives a Buy From Piper Sandler
BioMarin Pharmaceutical Insiders Sold US$6.7m Of Shares Suggesting Hesitancy
Over the past year, many BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying
BMO Sees BMRN, LEGN, SLN as Attractive M&A Targets
Peering Into Biomarin Pharmaceutical's Recent Short Interest
Biomarin Pharmaceutical's (NYSE:BMRN) short percent of float has risen 17.39% since its last report. The company recently reported that it has 3.56 million shares sold short, which is 1.89% of all reg
Here's Why Parnassus Value Equity Fund Sold BioMarin Pharmaceutical (BMRN)
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
9 analysts have expressed a variety of opinions on Biomarin Pharmaceutical (NASDAQ:BMRN) over the past quarter, offering a diverse set of opinions from bullish to bearish.The table below offers a cond
BioMarin Pharmaceutical Is Maintained at Overweight by Wells Fargo
BioMarin Pharmaceutical Is Maintained at Overweight by Wells Fargo
Biomarin Pharmaceutical Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 38.86% Wells Fargo $110 → $115 Maintains Overweight 05/17/2024 -13.06% Baird $104 → $72 Downgra
Wells Fargo Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Raises Target Price to $115
Wells Fargo analyst Mohit Bansal maintains $Biomarin Pharmaceutical(BMRN.US)$ with a buy rating, and adjusts the target price from $110 to $115.According to TipRanks data, the analyst has a success ra
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 41% Below Their Intrinsic Value Estimate
Daily short sale tracking: Sirius XM's short volume increased by 121 million, with a short sale ratio of 38%
Sirius XM(SIRI.US) ranked top of the list had the largest change in short volume (121.23 million shares), and the short volume ratio of Pembina Pipeline(PBA.US) reached 61.63%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Share Price Matching Investor Opinion
BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) price-to-earnings (or "P/E") ratio of 77.8x might make it look like a strong sell right now compared to the market in the United States, where around half